Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arixa Pharmaceuticals
Palo Alto, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead compound ARX‑1796, an oral prodrug of avibactam, demonstrated 60–80% absorption when administered orally in humans during a Phase 1 clinical trial. This enables the potential for the first novel oral beta-lactamase inhibitor + antibiotic combination in over three decades. The company was acquired by Pfizer to advance further development[1][2][5][6].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (oral prodrugs of beta-lactamase inhibitors)
- Industry
- Biotech
02
Partnerships
Pfizer Hospital Business division acquired and continues development of lead asset[1]
Beyond the preview
Go deeper on Arixa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arixa Pharmaceuticals.